Emma Brown

Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer

Noel W. Clarke, Andrew J. Armstrong, Antoine Thiery-Vuillemin et al. · NEJM Evidence · 2022 · 394 citations

Medicine, Oncology, Pharmacology +17

Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial

Fred Saad, Noel W. Clarke, Mototsugu Oya et al. · The Lancet Oncology · 2023 · 288 citations · Full text

Medicine, Oncology, Pharmacology +16

Rehabilitation versus surgical reconstruction for non-acute anterior cruciate ligament injury (ACL SNNAP): a pragmatic randomised controlled trial

David Beard, Loretta Davies, Jonathan Cook et al. · The Lancet · 2022 · 135 citations · Full text

Medicine, Orthopedic Surgery, Surgery +17

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

Martin Schüler, James Chih‐Hsin Yang, K. Park et al. · Annals of Oncology · 2015 · 132 citations · Full text

Medicine, Oncology, Pharmacology +13

PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Fred Saad, Andrew J. Armstrong, Antoine Thiery-Vuillemin et al. · Journal of Clinical Oncology · 2022 · 80 citations

Medicine, Oncology, Pharmacology +17